LIQUIDIA CORP (LQDA)
US53635D2027 - Common Stock
LQDA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While LQDA seems to be doing ok healthwise, there are quite some concerns on its profitability. LQDA is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
LQDA had negative earnings in the past year.
LQDA had a negative operating cash flow in the past year.
In the past 5 years LQDA always reported negative net income.
LQDA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LQDA has a Return On Assets of -66.35%. This is in the lower half of the industry: LQDA underperforms 65.64% of its industry peers.
LQDA has a Return On Equity of -166.01%. This is in the lower half of the industry: LQDA underperforms 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.35% | ||
| ROE | -166.01% | ||
| ROIC | N/A |
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LQDA has a Gross Margin of 83.52%. This is amongst the best in the industry. LQDA outperforms 86.67% of its industry peers.
In the last couple of years the Gross Margin of LQDA has declined.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LQDA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LQDA has more shares outstanding
LQDA has a worse debt/assets ratio than last year.
2.2 Solvency
LQDA has an Altman-Z score of 2.00. This is not the best score and indicates that LQDA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.00, LQDA is doing good in the industry, outperforming 69.74% of the companies in the same industry.
A Debt/Equity ratio of 0.92 indicates that LQDA is somewhat dependend on debt financing.
LQDA has a worse Debt to Equity ratio (0.92) than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
A Current Ratio of 4.85 indicates that LQDA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.85, LQDA is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
A Quick Ratio of 4.85 indicates that LQDA has no problem at all paying its short term obligations.
The Quick ratio of LQDA (4.85) is better than 65.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.85 |
3. Growth
3.1 Past
LQDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.47%.
Looking at the last year, LQDA shows a quite strong growth in Revenue. The Revenue has grown by 9.73% in the last year.
The Revenue has been growing by 45.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-76.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-366.67%
Revenue 1Y (TTM)9.73%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Revenue growth Q2Q-15.47%
3.2 Future
LQDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.29% yearly.
Based on estimates for the next years, LQDA will show a very strong growth in Revenue. The Revenue will grow by 73.69% on average per year.
EPS Next Y2.55%
EPS Next 2Y30.78%
EPS Next 3Y32.34%
EPS Next 5Y20.29%
Revenue Next Year230.6%
Revenue Next 2Y210.52%
Revenue Next 3Y128.71%
Revenue Next 5Y73.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LQDA's earnings are expected to grow with 32.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.78%
EPS Next 3Y32.34%
5. Dividend
5.1 Amount
No dividends for LQDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIQUIDIA CORP
NASDAQ:LQDA (5/1/2024, 9:38:00 AM)
13.14
+0.29 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap999.03M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.35% | ||
| ROE | -166.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-76.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y2.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.73%
Revenue growth 3Y186.97%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y